source
- FDA approves first radioligand generic, pitting Curium against Novartis' LutatheraThe U.S. Food and Drug Administration has granted approval to Curium’s radioligand product, the first generic in this therapeutic class. The approved drug is a direct equivalent of Novartis’ Lutat…
- Centric Compounding initiates nationwide recall of three injectable drugs due to API contaminationCentric Compounding, a Houston-based pharmacy, announced a nationwide recall of three injectable products after detecting contamination in an active pharmaceutical ingredient. The recall includes…